Financial Performance - In 2025, the company achieved operating revenue of 1,676.75 million yuan, representing a year-on-year increase of 14.95% [3] - The net profit attributable to the parent company was 310.83 million yuan, up 23.48% year-on-year [3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 305.98 million yuan, reflecting a year-on-year growth of 28.90% [3] Financial Position - As of the end of the reporting period, the company's total assets amounted to 3,646.89 million yuan, an increase of 7.33% from the beginning of the period [4] - The equity attributable to the parent company reached 3,285.55 million yuan, growing by 8.60% compared to the start of the period [4] - The net asset per share attributable to the parent company was 18.93 yuan, which is a 9.32% increase from the beginning of the period [4] Business Performance Factors - The growth in revenue for 2025 was primarily driven by the pharmaceutical and electronic materials sectors, with the pharmaceutical sector benefiting from inventory adjustments by key clients and increased sales of core products [5] - The electronic materials sector saw growth due to successful validation of semiconductor photoresist monomer materials and the introduction of certain packaging materials [5] - The company focused on enhancing operational efficiency and cost reduction, which contributed to improved profitability [5]

报告期内，显示材料板块平稳发展，2025年度收入增长主要体现在医药及电子材料板块，其中医药板块 主力产品客户调整库存策略、核心产品进一步放量，推动销售收入增长;电子材料板块随着公司半导体 光刻胶单体材料验证工作的顺利推进，并成功导入部分封装材料产品，带动了相关业务的增长。本年度 公司持续着力提升经营管理效率，深化降本增效，通过节约挖潜、精益流程进一步完善管理体系，强化 研产供销协同，降低生产成本，推动盈利能力提升。 瑞联新材(688550.SH)披露2025年度业绩快报，2025年度实现营业收入16.77亿元，同比增长14.95%;归属 于母公司所有者的净利润3.11亿元，同比增长23.48%。 ...

智通财经APP讯，瑞联新材(688550.SH)披露2025年度业绩快报，2025年度实现营业收入16.77亿元，同 比增长14.95%;归属于母公司所有者的净利润3.11亿元，同比增长23.48%。 报告期内，显示材料板块平稳发展，2025年度收入增长主要体现在医药及电子材料板块，其中医药板块 主力产品客户调整库存策略、核心产品进一步放量，推动销售收入增长;电子材料板块随着公司半导体 光刻胶单体材料验证工作的顺利推进，并成功导入部分封装材料产品，带动了相关业务的增长。本年度 公司持续着力提升经营管理效率，深化降本增效，通过节约挖潜、精益流程进一步完善管理体系，强化 研产供销协同，降低生产成本，推动盈利能力提升。 ...

Core Viewpoint - 瑞联新材 (688550.SH) reported a strong performance for the fiscal year 2025, with significant growth in both revenue and net profit, driven by advancements in its pharmaceutical and electronic materials segments [1] Financial Performance - The company achieved an operating revenue of 1.677 billion yuan, representing a year-on-year increase of 14.95% [1] - The net profit attributable to shareholders reached 311 million yuan, marking a year-on-year growth of 23.48% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 306 million yuan, reflecting a year-on-year increase of 28.90% [1] Segment Performance - The revenue growth in 2025 was primarily driven by the pharmaceutical and electronic materials segments [1] - In the pharmaceutical segment, sales revenue increased due to clients adjusting inventory strategies and a further increase in core product sales [1] - The electronic materials segment saw growth as the company successfully advanced its semiconductor photoresist monomer material validation and introduced some packaging materials products [1] Operational Efficiency - The company focused on enhancing operational management efficiency and deepening cost reduction and efficiency improvement measures [1] - Efforts included cost savings, process optimization, and strengthening the coordination of research, production, supply, and sales to lower production costs and enhance profitability [1]

Core Viewpoint - The company, Ruilian New Materials, has multiple semiconductor photoresist monomer materials in reserve, with several already in mass production and others undergoing customer validation stages [1] Group 1 - The company has developed several types of semiconductor photoresist monomer materials [1] - Some of the photoresist monomer materials have already entered mass production [1] - A portion of the products is currently in the customer validation phase, while others are in downstream customer verification stages [1]

Core Viewpoint - The company, Ruian New Materials (688550.SH), highlights the lengthy verification process required for the mass production of photoresist materials, which can take over two years before reaching production readiness [1] Group 1: Production Process - The mass production of photoresist materials involves several rigorous verification stages, including basic process assessment, small batch trial production, medium batch trial production, and mass production qualification [1] - The company's photoresist monomer materials must undergo multiple procedures and batches of validation before clients can conduct basic process assessments, resulting in a longer R&D to mass production cycle [1] Group 2: Product Status - The company has several types of semiconductor photoresist monomer materials in reserve, with some already in mass production [1] - Certain products are currently in the client validation stage, while others have entered the downstream validation phase with clients [1]

Financial Performance - The company reported a revenue of approximately 806.23 million, representing a year-on-year increase of 16.27% compared to the previous year's 693.44 million [1] - The total profit reached approximately 187.73 million, marking a significant increase of 72.42% from 108.88 million in the same period last year [1] - The net profit attributable to shareholders was approximately 166.08 million, up 74.22% from 95.33 million year-on-year [1] - The net profit after deducting non-recurring gains and losses was approximately 163.14 million, reflecting an 86.66% increase from 87.40 million in the previous year [1] - The net cash flow from operating activities was approximately 136.17 million, showing a slight decrease of 1.97% compared to 138.90 million last year [1] Segment Performance - The display materials segment generated sales revenue of 62.86 million, accounting for 78% of the company's total revenue, but saw a decline of 5.49% compared to the previous year [2] - The decline in the display materials segment was attributed to cautious demand from downstream manufacturers due to inventory control and changes in the international trade environment [2] - The electronic materials segment achieved sales revenue of 2.75 million, representing a substantial growth of 431.76% year-on-year, driven by successful product validation and the commencement of mass production [4] Market Dynamics - The increase in overall revenue was primarily driven by sales growth in the pharmaceutical and electronic chemical sectors, alongside improved cost management and a higher proportion of high-margin products in the pharmaceutical segment [1] - The display materials segment's performance was negatively impacted by a cooling market demand as manufacturers adopted production control and inventory reduction strategies [2]

Core Viewpoint - The company achieved record high quarterly performance in Q2 2025, with significant growth in revenue and net profit, driven by state-owned capital control and expansion into downstream materials [1][2]. Financial Performance - For H1 2025, the company reported revenue of 806 million yuan, a year-on-year increase of 16.3%, and a net profit of 166 million yuan, up 74.2% year-on-year [1]. - In Q2 2025, revenue reached 462 million yuan, reflecting a year-on-year growth of 26.5% and a quarter-on-quarter increase of 34.4%. Net profit for Q2 was 120 million yuan, showing a year-on-year increase of 97.5% and a quarter-on-quarter rise of 163.9% [1]. - The company adjusted its profit forecasts for 2025, expecting net profits of 335 million yuan, 403 million yuan, and 460 million yuan for 2025-2027, with corresponding EPS of 1.93, 2.32, and 2.65 yuan per share [1]. Business Segments - In H1 2025, revenue from display materials, pharmaceutical intermediates, and electronic materials was 629 million yuan, 150 million yuan, and 27 million yuan, respectively, with year-on-year changes of -5.49%, +548.61%, and +431.76% [2]. - The pharmaceutical business showed strong performance due to inventory adjustments by key clients and the continued ramp-up of core and new products [2]. Profitability - For H1 2025, the company reported a gross margin of 47.01% and a net margin of 20.6%, which improved by 8.12 and 6.85 percentage points year-on-year, respectively [3]. - In Q2 2025, gross margin and net margin were 50.39% and 26.06%, respectively, with quarter-on-quarter increases of 7.91 and 12.79 percentage points [3]. - The improvement in profitability was attributed to the strong performance of the pharmaceutical segment and effective cost control measures [3].